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Structure-guided drug discovery emerged in the 1970s and 1980s, stimulated by the 3D-structures of 
protein targets that became available, mainly through X-ray crystal structure analysis, assisted by 
development of synchrotron radiation sources. Structures of known drugs or inhibitors were used to 
guide the development of leads.   The growth of high-throughput screening during the late 1980s and 
the early 1990s in the pharmaceutical industry of chemical libraries of hundreds of thousands of 
compounds of molecular weight of ~500 Da was impressive, but still explored only a tiny fraction of 
the chemical space of the predicted 1040 drug-like compounds.  The use of fragments with molecular 
weights less than 300 Da in drug discovery, not only decreased the chemical space needing exploration 
but also increased promiscuity in binding targets. Here we discuss advances in X-ray fragment 
screening and the challenge of identifying sites where fragments not only bind but can be chemically 
elaborated while retaining their positions and binding modes. We first describe the analysis of fragment 
binding using conventional X-ray difference Fourier techniques, using M. abscessus SAICAR 
synthetase (PurC) as an example. We observe that all fragments occupy positions predicted by 
computational hotspot mapping. We compare this with fragment screening at Diamond Synchrotron 
Light Source XChem facility using PanDDA software, which identifies many more fragment hits, only 
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some of which bind to the predicted hotspots. Many low occupancy sites identified may not support 
elaboration to give adequate ligand affinity, although they will likely be useful in drug discovery as 
“warm spots” for guiding elaboration of fragments bound at hotspots.  We discuss the implications of 
these observations for fragment screening at the synchrotron sources. 
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Background 
Structure-guided drug discovery has its origins in both academia and the pharmaceutical industry in the 
1970s (for reviews see (1, 2)). The need to modify and elaborate natural compounds and other molecules 
found to inhibit target proteins began to stimulate interest in the crystal structures of proteins that were 
becoming available (3). The structural information of aspartic proteinases such as renin as a target for 
anti-hypertensives (4, 5) and HIV protease in the 1980s for AIDS (6, 7) demonstrated the value of 
detailed knowledge of protein-ligand interactions in the design of new compounds. In parallel in the 
late 1980s and 1990s the development of High Throughput Screening (HTS) led to construction of 
chemical libraries of millions of compounds. However, the huge size and diversity of “chemical space”, 
estimated to be 1040 molecules for drug-like compounds of molecular weights of ~500 Da, began to be 
a focus, as the pharma industry realized that existing large chemical libraries explored only a very small 
part of chemical space. An alternative approach to the challenge was found in decreasing the size of the 
molecules from molecular weight of ~500 Da to less than 300 Da, which not only decreased the size of 
chemical space needing exploration, but at the same time increased their promiscuity in binding targets. 
This laid down the basic principles of fragment-based drug discovery (FBDD) [see (2), for review]. 
 
Early fragment screening approaches included those at Abbott using ligand-based NMR (8) and at 
Astex using X-ray analysis (9), developed initially by exploiting high-throughput analysis of cocktails 
of six to ten fragments soaked into apo-protein crystals (10).  Knowledge of the structure of the complex 
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of the fragment with the target protein allowed the initial use of small, often non-chiral compounds, 
which were optimized using structure-guided approaches to make specific interactions and to introduce 
chirality into the molecules. The fragment hits were capable of achieving high binding efficiency per 
atom and often better physicochemical properties in comparison to those from HTS, which exploits 
much larger libraries of ~105 or even 106 compounds. 
 
With encouragement and funding from the Bill and Melinda Gates Foundation in 2006 the structure-
guided fragment-based drug discovery developed in Cambridge was spun back from Astex into the 
University with an initial focus on targeting Mycobacterium tuberculosis resulting in some success in 
producing lead and candidate molecules (11). Structure-guided fragment-based drug discovery is 
particularly well suited to academia in requiring inexpensive fragment libraries and depending on 
molecular biology, preparative biochemistry, structural, computational and biophysical methods 
available in academic structural-biology laboratories. This encouraged the extension of its use in 
targeting other mycobacterial targets including Mycobacterium abscessus, an increasing problem for 
cystic fibrosis patients, and Mycobacterium leprae where leprosy remains a major challenge in many 
parts of the world, with 211,973 new cases reported globally in 2015 (12). 
 
During the past four decades, synchrotron radiation facilities have played an increasingly central role 
in structure-guided drug discovery.  The pharmaceutical industry was initially sometimes hesitant to 
exploit the facilities, because they concerned crystals involving compounds with large intellectual 
property (IP) value to be sent outside the company. In academia this was less of a challenge, with the 
focus often being on early discovery rather than securing IP and in the study of neglected diseases, 
where the financial returns are unlikely to be great given their prevalence in developing countries or 
small patient populations.  However, pharmaceutical industry has become a major driver for increased 
automation at synchrotrons world-wide, often using beamlines built by individual companies.  Along 
with continuous improvements in beam intensity, detector technology, robotic sample handling and 
data analysis software, the speed and accuracy of the diffraction experiments have been systematically 
transformed (13).  These developments have made it possible to make fragment screening by X-ray 
structure routinely and widely accessible. 
 
 A major advance has been the XChem facility at the Diamond synchrotron (14) which has implemented 
further streamlining of crystal preparation (15). This development has been combined with the new 
Pan-Dataset Density Analysis (PanDDA) tool (16) that increases sensitivity, revealing fragments in 
even partially occupied binding sites by contrasting multiple unbound and ligand-bound-protein X-ray 
data sets to extract signals for bound fragments.  
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Although there has been intense use of XChem (14) and PanDDA software (16, 17) at Diamond and an 
awareness that many more fragment-binding sites tend to be identified, there has been little work on 
specific targets in comparing the new approach with the earlier one using standard difference Fourier 
X-ray analysis, usually assuming full occupancy of ligands on the same target protein. Here we discuss 
the use of an ongoing structure-guided fragment-based drug-discovery programme to compare the two 
approaches. The target selected, PurC, or phosphoribosylaminoimidazole-succinocarboxamide 
(SAICAR synthetase) from M. abscessus, is involved in the biosynthesis of purine nucleotides (18). 
The enzyme catalyzes the eighth step of the de novo purine biosynthesis pathway in bacteria and fungi, 
mediating the ligation of L-aspartate with 5-amino-1-(5-phospho-D-ribosyl) imidazole-4-carboxylate 
(CAIR) in the presence of ATP and Mg2+ to form SAICAR, as shown in Figure 1A . The importance 
of de novo purine biosynthesis in maintaining viability of cells and differences in structural architecture 
of bacterial and human PurC orthologs makes it an ideal target for anti-microbial agents (19-21), as 
further illustrated in the supplementary data and Figure S1. 
In this study, we focus on the fragment binding modes of MabPurC defined by X-ray analysis at the 
synchrotron using the standard difference Fourier approach, following preliminary screening of a 
fragment library using biophysical techniques such as differential scanning fluorimetry (DSF) and 
isothermal titration calorimetry (ITC). We then describe recent experiments on PurC at the Diamond 
light source at the Rutherford Laboratory using the high-throughput and roboticised X-ray screening 
method, XChem, developed by von Delft and colleagues (14). This, together with PanDDA software 
(16, 17), exploits the multiple apo-protein crystal structures from the synchrotron X-ray screening that 
have no fragments bound, resulting in a more accurate description of both the apo-enzyme structure 
and the fragment binding and occupancy in the complex.  
We also compare the experimental fragment-binding sites derived using the two X-ray approaches with 
those predicted by the use of by Fragment Hotspot Maps (22), where hot spots are defined 
computationally by their ability to bind a small molecule fragment. The software exploits experience 
of fragment-binding experiments over many years indicating that binding sites tend to have polar donor 
and/or acceptor binding capability as well as non-polar regions in close proximity. It is assumed that 
this limits not only the translational but also the rotational entropy of water molecules at the sites in the 
apostructures, so making the release of the “unhappy” waters more entropically favorable and their 
replacement by a fragment more favored. The entropic gain in release also tends to be further increased 
by release of fragments from deeper pockets, where rotational freedom is further limited. These features 
were built into Fragment Hotspot Maps, developed by Radoux et al. (22). 
Here the focus is to compare the new developments in fragment-based drug discovery at XChem with 
those used over the past two decades, mainly aided by synchrotron radiation, using MabPurC as an 
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example of a drug discovery target. We briefly describe the information about PurC activity and 
structure, which is necessary for understanding the fragment binding using the two experimental 
approaches. We do not discuss the next stages of fragment-linking or chemical elaboration, which are 
being pursued in parallel for PurC as a target for combatting infections by M. abscessus in cystic 
fibrosis.  
Results  
Overall structure of Mycobacterium abscessus PurC & substrate binding 
The apo-structure of MabPurC was solved and refined at 1.5 Å resolution.   The crystals are similar to 
those of a previously determined structure of MabPurC with a monomer in the asymmetric unit (Figure 
1B) (PDB 3R9R, Seattle Structural Genomics Consortium for Infectious Diseases). Mycobacterium 
abscessus PurC (MabPurC), like other PurC orthologues, is a globular protein consisting of two lobes 
spanning a long catalytic cleft.  To investigate further the substrate interactions in the PurC catalytic 
cleft, the crystal structure of Mycobacterium abscessus PurC in complex with ATP was solved at 1.2 Å 
resolution, following co-crystallization of the protein with ATP. The resulting structure shows that ATP 
occupies one end of the active site cleft with the phosphate groups extending towards a positively 
charged pocket towards the middle of cleft. Superposition of the MabPurC: ATP structure  with that of 
E. coli PurC: CAIR bound form (PDB code 2GQS) shows that the catalytic cleft contains sites for ATP 
at one end and CAIR at the other (Figure 2 B). It has been proposed previously that L-aspartate may 
occupy the space between ATP and CAIR (23, 24).  
 
 
Figure 1: A) Schematic depiction of the enzyme reaction catalysed by PurC (SAICAR synthetase) in 
the bacterial Purine biosynthesis pathway. B) Crystal structure of apo form of M. abscessus PurC 
refined at 1.5 Å resolution, coloured by secondary structure. 
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Initial Fragment Screening & Characterization of Hits 
Our initial fragment screening approach used methods developed in Cambridge in Astex and in the 
University (for a review see 11). A library of 960 small molecule fragments was screened by differential 
scanning fluorimetry (DSF), resulting in 43 hits, which were then investigated by X-ray crystallography 
using the standard difference Fourier approach. MabPurC apo-crystals were soaked with each fragment 
in individual experiments. The eight fragment hits identified form the resulting crystal structures were 
all found to occupy the ATP pocket of MabPurC, recapitulating key binding interactions of the adenine 
ring (Figure 2 & Supplementary data Table 1) in the structure of MabPurC. 
 
As illustrated in Figures 2 C & D, the binding modes of fragments 1 and 2 are similar to those of the 
ATP adenine ring in this region. These include H-bond interaction to the His69 side chain and to the 
backbone amide nitrogens of Leu93 and Asp213 and backbone carbonyl of Arg91, and many water-
mediated hydrogen bonds in the active site. π-interactions of the fragments are mainly mediated by the 
side chain of Met95 at the edge of the active site cleft. Many fragments also engage in stacking and 
hydrophobic interactions with the side chains of Leu27 at the top of the cleft. However, marked 
differences were observed in the orientation of the planar ring of the fragments at the adenine pocket 
depending on the ring variant and chemical substitutions. The binding interactions of all the above 
fragment hits with MabPurC were further characterised by ITC and the calculated Kd values ranged 
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Figure 2: M. abscessus PurC in complex with natural ligands and fragment hits. A) Crystal structure 
of Mab PurC in complex with ATP (blue) showing the position of fragments 1 (pink) & 2 (green) with 
respect to ATP adenine ring; B) Crystal structure of Mab PurC in complex with ATP (blue) and the 
inferred position of substrate CAIR (green) in MabPurC derived by superposition with E. coli PurC 
(PDB code 2GQS); C) fragment 1 and D) fragment 2, showing interaction of fragment hits (yellow 
stick) with residues at the ATP site (grey stick). Hydrogen bonding interactions are depicted in blue, π- 
interactions in black and hydrophobic contacts in red dotted lines respectively. The corresponding 2D 
structures of fragments and biophysical data are shown below.  
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Computational hotspot mapping of M. abscessus PurC  
The MabPurC structure was further analysed using Fragment Hotspot Maps	  (22), with the objective of 
investigating the binding propensities of ligands.  Work with M. abscessus, M. leprae and M. 
tuberculosis (Thomas SE, Mendes V, Vedithi SC and Blundell TL, unpublished) indicates that the 
software is able to reproduce natural ligand sites when using contour levels of 17 and above. Contour 
level 14 additionally reveals “warm spots” where a fragment may not bind but where further interactions 
can stabilize a ligand as it is grown from a fragment bound to an adjacent hotspot. 
 
Superposition of the resulting hotspot map, contoured at 17, with the previously defined ATP- and 
CAIR-bound structures show three hotspot regions within the active site cleft (Figure 3A) and an 
additional small hotspot pocket on the distal side (Figure 3B). The first hotspot is in the ATP adenylyl-
binding region, with residues 91RRLDM95 and His 69 providing three H-bond acceptor and one donor 
interactions. Most fragments that bind in this pocket also satisfy the hydrogen bond donor (blue), 
acceptor (red) and hydrophobic (yellow) interactions of hotspot 1.  
 
When the same map is observed at contour 14, an additional “warm spot” (warm spot 
 2) region can be seen adjacent to the flexible loop and β-hairpin at the end of the hotspot 1 with residues 
such as Arg17 binding the ATP phosphate groups (Figure 3C). This region thus provides a potential 
area for developing fragments from hotspot 1 further into the catalytic cleft. At hotspot 3, a possible 
hydrogen bond donor was observed matching the CAIR phosphate bind site, although the hydrophobic 
feature (yellow) of the hotspot is not well defined, unless when observed at contour 14, potentially 
explaining why no fragments were seen to bind in soaking experiments. The hotspot 4 at the edge of 
the catalytic site further beyond the ATP and CAIR binding sites and the additional hotspot 5 on the 
rear of the protein (Figure 3 B & D) could represent an allosteric site, the biological relevance of which 
requires further investigation. 
 
                                                                                     	  





Figure 3: Hotspot mapping of PurC. Crystal structure of MabPurC protein (white), shown in surface 
representation, with hotspot maps showing hydrogen bond donor (blue), acceptor (red) and 
hydrophobic (yellow) regions. ATP (blue stick) and CAIR (green stick) are also shown. A) Three hotspot 
regions are observed at the active site cleft at the front, when the maps are contoured at 17 B) A fifth 
hotspot consisting of an acceptor region is seen at the rear of the protein. C) A warm spot (Warm spot 
2) can also be seen in addition to the three hotspots, when the maps are contoured at 14 and the 
hydrophobic patches (yellow) at all the hotspot regions become more prominent at this contour D) the 
fifth hotspot at the rear of the protein when observed at contour 14. The hotspot maps were generated 
as described in (22). 
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Fragment Screening using XChem & PanDDA with a diverse library  
Fragment hits from the in-house fragment library all occupy the ATP indole pocket of MabPurC. To 
identify additional hotspots in PurC we increased the chemical diversity of the library. Two libraries 
were employed. The first, the Leeds 3D collection (25, 26), comprises 125 fragments with fewer planar 
chemical groups and more natural-product-like scaffolds. Fragments from this library have high sp3 
content providing more opportunities for elaboration. The second, the Diamond-SGC-iNext Poised 
Library, comprises 768 chemically diverse fragments with at least one functional group to allow a 
simplified chemical synthesis (27). The hits from our in-house library (see above) were included as a 
positive control in the screening experiments. 
 
The PanDDA method utilizes a collection of related crystallographic data sets to identify regions within 
individual sets that are statistical outliers, for example indicating a changed conformational state due to 
ligand binding. A partial-difference or event map is created to reflect the density for the bound-state 
only. This is done by subtracting a proportion of the apo-structure; the fragment-bound states are 
identified from analysis of density distributions. The ensemble models are then refined with the help of 
standard resolution-dependent refinement procedures (16, 17).  
 
304 crystal structures were solved and 88 event maps identified by the PanDDA program were manually 
verified in Coot (28, 29) and fragments were modelled and refined in 35 of them (Figure 4). Almost 
60% of all the identified hits occupy the first hotspot region of PurC corresponding to ATP adenylyl 
pocket. The positive controls (in-house library hits) were also analysed using the PanDDA method and 
found to adopt binding mode close to those previously determined in our laboratory.  
 
In addition, several new hits and chemical scaffolds were identified at the same site from the more 
diverse fragments in the libraries used in this study. These compounds bound with occupancies ranging 
from 1.0 - 0.7. This includes 3-dimensional fragment XC1, in which the pyridine ring of the fragment 
makes hydrophobic and π-stacking interactions with the side chains of Leu19 and Arg17 respectively. 
Interestingly the flexible chain with a halogen atom binds in the negatively charged sub-pocket, adjacent 
to the ATP adenine site at hotspot 1, where it interacts with side chains of Glu99 and Glu200 as well as 
active-site water molecules (Supplementary Data Figures S2 A & B ). This sub-pocket was not 
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Figure 4:  Fragment binding modes identified from screening of diverse fragment libraries by 
crystallography and analysis using PanDDA program. Hotspot maps are contoured at 14 and 
MabPurC protein is shown as surface electrostatic representation A) Front view of the protein with 
fragment binding sites 1-5 and representative hits. B) Rear view of the protein having fragments binding 
sites 6-8 with representative hits. The average occupancies and B-factors corresponding to each site 
are also illustrated in blue box.  
 
Apart from numerous fragment hits hotspot 1 (ATP adenylyl site), the only other hotspot with an 
observed hit was number XC2, at the PurC active site cleft edge near the CAIR binding region. This 
fragment exhibits a low occupancy of 0.4 and forms H-bonds from its amino group to the side chain of 
Arg222 and from its sulphur atom to the amide of Gly108 and the hydroxyl group of Thr107 (see 
Supplementary Data Figures S2 C & D). 
 
Interestingly, no fragment hits were observed at predicted warms pot region corresponding to the site 
2- aspartic acid binding region and hotspot 3- substrate (CAIR) site of the PurC protein from either the 
in-house or PanDDA method indicating that these two sites may not be true hotspot regions. Indeed, 
the corresponding maps for the region are less evident when set at a higher cut-off (contour >17), while 
hotspot maps corresponding to site 1 (ATP adenylyl pocket), 4 (edge of the active site cleft) and 5 (at 
the rear of the protein) remain unchanged even at a more stringent cut-off. 
 
The remaining fragment hits identified from the PanDDA analysis do not involve any of the predicted 
hotspot regions but instead form weak interactions in shallow binding pockets, some near 
crystallographic symmetry axes. This is not surprising given that the PanDDA method is sensitive to 
low occupancy fragments resulting in weak density.  
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Discussion 
The aim of screening the essential enzyme M. abscessus SAICAR synthetase (PurC) for fragment 
binding was to assess its usefulness as a target of antimicrobial drug discovery. We compare two 
different approaches to identify fragment binding sites. Screening the enzyme against an in-house 
fragment library of 960 fragments resulted in eight hits that were bound to the adenine pocket of the 
PurC ATP binding site. Interactions of these fragments were investigated by X-ray crystallographic and 
isothermal calorimetry (ITC) analyses. Fragment 2 was found to have a Kd of below 350µM, indicating 
promising starting points for chemical elaboration.  For PurC, we observe that all the fragments 
identified from standard difference maps occupy positions predicted by the computational hotspot 
mapping software (22).  
 
Further fragment screening experiments of PurC were undertaken at the Diamond Light Source XChem 
facility using two chemically diverse fragment libraries. Resulting crystallographic datasets sets were 
density averaged and ensemble-modelled using PanDDA software. Again fragment-binding site 1 
predominated. Of the three interesting hits two occupy a negatively charged sub-pocket adjacent to the 
ATP adenine-binding site as well as site 1, providing starting points for chemical merging or linking 
with previously identified fragments.  A third fragment binds at a small pocket at the edge of the 
catalytic cleft adjacent to substrate CAIR binding region. If this interaction can be replicated, the 
fragment may be amenable for further intervention to develop a non-ATP competitive inhibitor of PurC 
enzyme. Thus, these experiments using diverse chemical libraries with 3D chemical scaffolds together 
with the PanDDA method were able to identify new sub-pockets on which to build a future fragment-
based drug discovery campaign. .  
 
The most challenging aspect of the XChem and PanDDA approach is the identification of many  
fragment hits that bind to protein sites with low occupancies (Figure 4). Are these sites truly hot spots 
unidentified by the default contour level 17 in Fragment Hotspot Maps program (22), or are they weak 
binding sites routinely seen in crystals due to high concentrations of ligand molecules? This could be 
investigated by establishing whether such fragments maintain their binding modes and interactions 
when elaborated into larger chemical entities. This is a challenge, requiring extensive chemistry, which 
we will follow up in the future with PurC and other targets. On the other hand, they may be “warm 
spots” where fragments are not bound with a sufficient gain of entropy to stabilize them when 
elaborated. These fragment hits may nevertheless be useful if sufficiently close to hotspots where a 
fragment is being elaborated to allow design of molecules that exploit further interactions, the price of 
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Materials & Methods 
Crystallization of M. abscessus PurC 
Initial screening of PurC protein for determining appropriate crystallization conditions involved the use 
of following commercially available sparse matrix screens: Drops containing 18 mg/mL of the protein 
in storage buffer (50mM Tris-HCl pH 7.5, 150 mM NaCl) and reservoir at two different drop ratios: 
0.3µL: 0.3µL & 0.6µL: 0.3µL (of protein: reservoir respectively) were set up using a Mosquito 
crystallization robot (TTP Labtech), in 96-well sitting drop (MRC-2) plates. The drops were 
equilibrated against 80 µL of the corresponding reservoir solution at 19°C. The best diffracting crystals 
(1.5 Å resolution) were obtained from JCSG well H9, 0.2M LiSO4, 0.1M Bis-Tris pH 5.5, 25% PEG 
3350 and this crystal condition was used for further experiments. 
 
Co-crystallization of M. abscessus PurC protein with ATP 
2mM-5mM final concentration of compound of ATP in DMSO/water was added to 18 mg/mL of PurC 
protein, mixed and incubated for 2 hrs on ice. Crystals were grown in the following condition: 0.2 M 
Lithium sulphate, 21-28% PEG3350, 0.1M Bis-Tris pH 5.5–6.5. The crystallization drops were set up 
at a protein to reservoir drop ratio of 0.3µL: 0.3µL, in 96-well (MRC2) sitting drop plate, using 
Mosquito crystallization robot (TTP Labtech) and the drops were equilibrated against 70 µL of reservoir 
at 19°C. 
 
Soaking of M. abscessus PurC native crystals with in-house fragment library  
Crystals for this experiment were grown at 19°C in 48-well sitting drop plates (Swiss CDI) in the 
following grid condition: 0.2M Lithium sulphate, 21-28% PEG3350, 0.1 M Bis-Tris pH 5.5–6.5. 
Further, the crystals were picked and allowed to soak in a 4 µL drop containing reservoir solution and 
10 mM fragments which was then equilibrated against 800 µL of the corresponding reservoir solution 
overnight at 19°C in a 24-well hanging drop vapour diffusion set up. 
 
X-ray Data Collection and processing 
The PurC apo- and ligand-bound crystals were flash-cooled in cryo-protectant containing precipitant 
solution and 25% Ethylene glycol. X-ray data sets were collected by the rotation method and pixel array 
detectors at Diamond Light Source in the UK, using beamlines I03, I04, I24 and I04-1 at wavelength 
of 0.979 Å (0.93 Å at I04-1), and at the Soleil French National Synchrotron facility at wavelength 
0.979 Å.  Datasets comprised a total oscillation of 210°-240° and oscillation angles of 0.15-1° per 
image, and total dataset exposure of 105-192 sec at Diamond, and 105-120 sec at Soleil. The diffraction 
images were processed using AutoPROC (30), utilizing  XDS (31) for indexing, integration, followed 
by POINTLESS (32), AIMLESS (33) and TRUNCATE (34) programs from CCP4 Suite (35) for data 
reduction, scaling and calculation of structure factor amplitudes and intensity statistics. All PurC 
crystals belonged to space group P21 and consisted of one promoter in the asymmetric unit. 
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Structure Solution and refinement 
The M. abscessus PurC apo-structure was solved by molecular replacement using PHASER (36) with 
the atomic coordinates of M. abscessus PurC at 1.85 Å (PDB entry: 3R9R, Seattle Structural Genomics 
Consortium for Infectious Diseases) as search model and PurC ligand bound structures were solved by 
molecular replacement with the atomic coordinates of the solved M. abscessus PurC Apo structure as 
search model. Structure refinement was carried out using REFMAC (37) and PHENIX (38). The models 
obtained were manually re-built using COOT interactive graphics program (28) and electron density 
maps were calculated with 2|Fo|- |Fc| and |Fo| - |Fc| coefficients. Position of ligands in the protein active 
site and water molecules were located in difference electron density maps and OMIT difference maps 
|mFo − DFc| (39) were calculated and analysed to further verify positions of fragments and ligands. 
 
Extended fragment library crystallographic screening using of XChem and PanDDA  
The crystals used in this study were grown at 19°C in 348-well 3 drop, sitting drop plates (Swiss CI) in 
the following grid condition: 0.2M Lithium sulphate, 21-28% PEG 3350, 0.1M Bis-Tris pH 5.5–6.5 
using PurC protein at a concentration of 18mg/mL equilibrated against 40µL reservoir. Apo crystals 
were allowed to soak in 30-50 mM fragments for 1 hr. Crystal soaking, harvesting, mounting and data 
collections were performed at the Diamond Light Source I04-1 beamline through the XChem facility 
workflow (14). After molecular replacement and refinement of the initial model, the resulting maps 
were analysed by PanDDa (16) followed by model building using Coot (28). The ensemble models are 
then refined with the help of standard resolution-dependent refinement procedures (16, 17).  
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